文献速递胸部肿瘤泌尿男性生殖肿瘤

追踪癌症 evolution:TRACERx 研究综述

Tracking Cancer Evolution through the Disease Course.
PubMed 文献 · Cancer Discov · 2021-01-01

TRACERx 研究于2014年启动,通过原发肿瘤多区域测序与纵向采样,追踪肿瘤内异质性与患者结局的关系。研究覆盖非小细胞肺癌与透明细胞肾细胞癌,揭示克隆新抗原靶向治疗及 ctDNA 检测用于辅助治疗微小残留病灶监测的潜力。

要点

  • 肿瘤内异质性由基因组不稳定驱动,包括突变、体细胞拷贝数改变和表观基因组变化。
  • TRACERx 通过多区域与纵向采样,在非小细胞肺癌和透明细胞肾细胞癌中刻画肿瘤与免疫微环境演化。
  • 靶向克隆新抗原及辅助治疗中 ctDNA 检测微小残留病灶具潜在治疗转化价值。

核心结论

  • TRACERx 研究通过多区域和纵向采样追踪癌症演化,揭示肿瘤内异质性与患者结局的关系。
  • 靶向克隆新抗原及辅助治疗中 ctDNA 检测微小残留病灶具有潜在治疗转化价值。

研究设计与样本

  • TRACERx 于2014年启动,为前瞻性招募患者队列研究,整合原发肿瘤多区域测序与纵向采样。
  • 研究追踪癌症从早期到晚期疾病及治疗过程中的演化。

主要发现

  • 肿瘤细胞在动态选择压力下竞争,表型变异表现为肿瘤内异质性,由基因组不稳定驱动。
  • 基因组不稳定导致突变、体细胞拷贝数改变和表观基因组变化。
  • 在非小细胞肺癌和透明细胞肾细胞癌中,研究详细描述了肿瘤及免疫微环境的演化过程。

临床怎么用

  • 靶向克隆新抗原可能成为治疗策略。
  • 辅助治疗中 ctDNA 检测可作为微小残留病灶检测工具,已准备进入临床试验转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During cancer evolution, constituent tumor cells compete under dynamic selection pressures. Phenotypic variation can be observed as intratumor heterogeneity, which is propagated by genome instability leading to mutations, somatic copy-number alterations, and epigenomic changes. TRACERx was set up in 2014 to observe the relationship between intratumor heterogeneity and patient outcome. By integrating multiregion sequencing of primary tumors with longitudinal sampling of a prospectively recruited patient cohort, cancer evolution can be tracked from early- to late-stage disease and through therapy. Here we review some of the key features of the studies and look to the future of the field. SIGNIFICANCE: Cancers evolve and adapt to environmental challenges such as immune surveillance and treatment pressures. The TRACERx studies track cancer evolution in a clinical setting, through primary disease to recurrence. Through multiregion and longitudinal sampling, evolutionary processes have been detailed in the tumor and the immune microenvironment in non-small cell lung cancer and clear-cell renal cell carcinoma. TRACERx has revealed the potential therapeutic utility of targeting clonal neoantigens and ctDNA detection in the adjuvant setting as a minimal residual disease detection tool primed for translation into clinical trials.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Bailey C, Black JRM, Reading JL, et al. Tracking Cancer Evolution through the Disease Course. Cancer Discov. 2021. PMID: 33811124. doi:10.1158/2159-8290.CD-20-1559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。